An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men

• Status: Withdrawn
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: Male

Summary

This is an open-study with a 26 week open label treatment period followed by an optional 26 week open label extension. The total treatment period will be 52 weeks.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AbbVie

Criteria

Inclusion Criteria:

Low testosterone

Exclusion Criteria:

• Normal testosterone levels

• Elevated Prostatic Specific Antigen (PSA)

• History of breast or prostate cancer